The DOI matches its Crossref record.
Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis.
Open accessAbstract
Recently, it has been shown that Factor XI can be activated by thrombin, and that Factor XIa significantly contributes to the generation of thrombin via the intrinsic pathway after the clot has been formed. This additional thrombin, generated inside the clot, was found to protect the clot from fibrinolysis. A plausible mechanism for this inhibitory effect of thrombin involves TAFI (thrombin-activatable fibrinolysis inhibitor, procarboxypeptidase B) which, upon activation, may inhibit fibrinolysis by removing carboxy-terminal lysines from fibrin. We studied the role of Factor XI and TAFI in fibrinolysis using a clot lysis assay. The lysis time was decreased twofold when TAFI was absent, when TAFI activation was inhibited by anti-TAFI antibodies, or when activated TAFI was inhibited by the competitive inhibitor (2-guanidinoethylmercapto)succinic acid. Inhibition of either TAFI activation or Factor XIa exhibited equivalent profibrinolytic effects. In the absence of TAFI, no additional effect of anti-Factor XI was observed on the rate of clot lysis. We conclude that the mechanism of Factor XI-dependent inhibition of fibrinolysis is through the generation of thrombin via the intrinsic pathway, and is dependent upon TAFI. This pathway may play a role in determining the fate of in vivo formed clots.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
High Levels of Coagulation Factor XI as a Risk Factor for Venous Thrombosis
Meijers, J. C. M., Tekelenburg, W. L. H., Bouma, B. N., Bertina, R. M., & Rosendaal, F. R. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003093421004 · Cited by 700
Self-citationOral Contraceptives and the Risk of Venous Thrombosis
Vandenbroucke, J. P., Rosing, J., Bloemenkamp, K. W. M., Middeldorp, S., Helmerhorst, F. M., Bouma, B. N., & Rosendaal, F. R. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105173442007 · Cited by 579
Self-citationPathogenesis and Pathophysiology of Pneumococcal Meningitis
Mook-Kanamori, B. B., Geldhoff, M., van der Poll, T., & van de Beek, D. (2011) · Clinical Microbiology Reviews · doi:10.1128/cmr.00008-11 · Cited by 492
What Does It Take to Make the Perfect Clot?
Monroe, D. M., & Hoffman, M. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000193624.28251.83 · Cited by 431
Reduced incidence of ischemic stroke in patients with severe factor XI deficiency
Salomon, O., Steinberg, D. M., Koren-Morag, N., Tanne, D., & Seligsohn, U. (2008) · Blood · doi:10.1182/blood-2007-10-120139 · Cited by 327
Pathophysiology and Treatment of Coagulopathy in Massive Hemorrhage and Hemodilution
Bolliger, D., Görlinger, K., Tanaka, K. A., & Warner, D. S. (2010) · Anesthesiology · doi:10.1097/aln.0b013e3181f22b5a · Cited by 325
Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis
Lisman, T., de Groot, P. G., Meijers, J. C. M., & Rosendaal, F. R. (2005) · Blood · doi:10.1182/blood-2004-08-3253 · Cited by 282
Self-citationLisman, T., Leebeek, F. W. G., Mosnier, L. O., Bouma, B. N., Meijers, J. C. M., Janssen, H. L. A., Nieuwenhuis, H. K., & De Groot, P. G. (2001) · Gastroenterology · doi:10.1053/gast.2001.25481 · Cited by 281
Self-citationThrombophilia and Venous Thromboembolism: Implications for Testing
Cohn, D., Roshani, S., & Middeldorp, S. (2007) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-2007-985753 · Cited by 75
“As is the case for prothrombin (FII), increased levels of coagulation FVIII, FIX, FXI, and fibrinogen increase the risk of VTE.25–28 In several studies, elevated FVIII levels were shown to be quite prothrombotic, with a dose-dependent 5- to 10-fold relative risk increase.25,29,30 For each 10% increase of FVIII, the VT…”
BackgroundInfluential
Metadata
- Authors
- Von dem Borne, P. A., Bajzar, L., Meijers, J. C., Nesheim, M. E., & Bouma, B. N.
- Venue
- Journal of Clinical Investigation
- Published
- 1997-05-15
- Volume
- 99
- Issue
- 10
- Pages
- 2323-2327
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2000971803
- Cited by
- 231
- References
- 0
- FWCI
- 4.26
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.